内容

颂通生物：虾青素开启小鼠长寿基因

夏威夷大学John A. Burns医学院和Cardax公司最近联合公布了一项动物研究的结果，他们对一种抗衰老药物的有效性进行了评估。

由Cardax公司开发的虾青素化合物CDX-085能够显著增强FOXO3基因的表达，之前有研究表明该基因与长寿有关。“每个人体内都有FOXO3基因，可以帮助人类对抗衰老，但是每三个人中可能就有一人体内携带另一种与长寿有关的FOXO3。通过激活普通人体内的FOXO3基因，我们就可以将其变成‘长寿’版的FOXO3。通过该研究我们证明了虾青素能够激活FOXO3基因。”Bradley Willcox教授这样说道。

这项初步研究首次在动物体内检测了虾青素对FOXO3基因的激活能力。在该研究中，研究人员用正常食物或包含了低剂量或高剂量虾青素化合物CDX-085的食物喂养小鼠，结果发现食物中含有更高剂量虾青素化合物的小鼠在其心脏组织中出现了FOXO3基因的表达增强。

“夏威夷大学的这项突破性发现进一步支持了虾青素对健康的有益作用，也解释了为何一些健康保健团体非常推崇虾青素，”Cardax公司CEO David G. Watumull这样说道。“我们希望能够在临床试验中进一步证实虾青素的抗衰老作用。”

“能够与Cardax公司在这个非常具有前景的项目上进行合作让我们感到非常满意，该研究或可帮助延缓人类衰老。这也是夏威夷创新计划的一个很好的例子，在该项目的联合之下私营企业与政府能够共同推动创新、研究、教育等方面，从而使经济实现多样化。”来自夏威夷大学的Vassilis L. Syrmos这样说道。

Astaxanthin compound found to switch on the FOX03 'longevity gene' in mice

The University of Hawaii John A. Burns School of Medicine ("JABSOM") and Cardax, Inc. ("Cardax") (OTCQB:CDXI), a Honolulu based life sciences company, have jointly announced the results of an animal study evaluating the effectiveness of a compound that holds promise in anti-aging therapy.

The Astaxanthin compound CDX-085 (developed by Cardax) showed the ability to significantly increase the expression of the FOXO3 gene, which plays a proven role in longevity.

"All of us have the FOXO3 gene, which protects against aging in humans," said Dr. Bradley Willcox, MD, Professor and Director of Research at the Department of Geriatric Medicine, JABSOM, and Principal Investigator of the National Institutes of Health-funded Kuakini Hawaii Lifespan and Healthspan Studies. "But about one in three persons carry a version of the FOXO3 gene that is associated with longevity. By activating the FOXO3 gene common in all humans, we can make it act like the "longevity" version. Through this research, we have shown that Astaxanthin "activates" the FOXO3 gene," said Willcox.

"This preliminary study was the first of its kind to test the potential of Astaxanthin to activate the FOXO3 gene in mammals," said Dr. Richard Allsopp, PhD, Associate Professor, and researcher with the JABSOM Institute of Biogenesis Research.

In the study, mice were fed either normal food or food containing a low or high dose of the Astaxanthin compound CDX-085 provided by Cardax. The animals that were fed the higher amount of the Astaxanthin compound experienced a significant increase in the activation of the FOXO3 gene in their heart tissue.

"We found a nearly 90% increase in the activation of the FOXO3 "Longevity Gene" in the mice fed the higher dose of the Astaxanthin compound CDX-085," said Dr. Allsopp.

"This groundbreaking University of Hawaii research further supports the critical role of Astaxanthin in health and why the healthcare community is embracing its use," said David G. Watumull, Cardax CEO. "We look forward to further confirmation in human clinical trials of Astaxanthin's role in aging."

"We are extremely proud of our collaborative efforts with Cardax on this very promising research that may help mitigate the effects of aging in humans," said Vassilis L. Syrmos, Vice President of Research at the University of Hawaii. "This is a great example of what the Hawaii Innovation Initiative is all about—when the private sector and government join forces to build a thriving innovation, research, education and job training enterprise to help diversify the state's economy."

更多颂通生物行业资讯请登录：http://www.chance-bio.com/